Last10K.com

Aegerion Pharmaceuticals, Inc. (AEGR) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2011

Aegerion Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1338042 Ticker: AEGR

Exhibit 99.1

 

LOGO

FOR IMMEDIATE RELEASE

CONFERENCE CALL DETAILS ON PAGE TWO

AEGERION PHARMACEUTICALS ANNOUNCES

FOURTH-QUARTER AND FULL-YEAR 2011 FINANCIAL RESULTS

Company Submits Marketing Applications for Lomitapide in US and EU

Cambridge, MA, March 6, 2012 -

Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced its financial results and business highlights for the fourth-quarter and year ended December 31, 2011. Aegerion recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of Aegerion’s lead investigational therapeutic, lomitapide, as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in patients with Homozygous Familial Hypercholesterolemia (HoFH). Late in the day on March 5, 2012, the FDA informed Aegerion that the NDA filing would receive standard review.

“We closed 2011 having made significant progress to ready ourselves for a potential commercial launch of lomitapide,” said Marc D. Beer, Chief Executive Officer. “Following our recent regulatory submissions, we have now turned our attention to working with the HoFH community to identify patients, educate on the disease and increase awareness. We entered 2012 with great momentum, having established a team highly experienced in the rare disease area. This team continues to be motivated by the potential to bring an important therapy to patients who currently have inadequate treatment options available.”

Fourth-Quarter and Year-End 2011 Corporate Highlights

 

  •  

In October 2011, Aegerion completed its Phase III clinical trial of lomitapide in adult patients with Homozygous Familial Hypercholesterolemia, and in January 2012, Aegerion announced that the 78-week results from the trial were consistent with data previously reported at the 26-and 56-week time points.

The following information was filed by Aegerion Pharmaceuticals, Inc. (AEGR) on Tuesday, March 6, 2012 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Aegerion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aegerion Pharmaceuticals, Inc..

Continue

Assess how Aegerion Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aegerion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2012 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools
Ticker: AEGR
CIK: 1338042
Form Type: 10-K Annual Report
Accession Number: 0001193125-12-117291
Submitted to the SEC: Thu Mar 15 2012 4:01:32 PM EST
Accepted by the SEC: Thu Mar 15 2012
Period: Saturday, December 31, 2011
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/aegr/0001193125-12-117291.htm